| Trial ID: | L3573 |
| Source ID: | NCT00511667
|
| Associated Drug: |
Mk0941
|
| Title: |
A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00511667/results
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: MK0941|DRUG: Comparator: Placebo
|
| Outcome Measures: |
Primary: Participants With Any Clinical Adverse Experience, Approximately 30 days after last dose of study drug (14 days for participants receiving MK0941 40 mg before each meal)|Participants Discontinued Because of Any Clinical Adverse Experience, Approximately 30 days after last dose of study drug (14 days for participants receiving MK0941 40 mg before each meal) | Secondary: Area Under the Concentration-time Curve (AUC0-24) of MK-0941 After Multiple Doses of MK0941, Up to 72 hours after dosing (up to 24 hours for participants receiving MK0941 60 mg before 2 meals each day)|Maximum Concentration (Cmax) of MK-0941 After Multiple Doses of MK-0941, Up to 72 hours after dosing (up to 24 hours for participants receiving MK0941 60 mg before 2 meals each day)|Time to Maximum Concentration (Tmax) of MK-0941 After Multiple Doses of MK-0941, Up to 72 hours after dosing (up to 24 hours for participants receiving MK0941 60 mg before 2 meals each day)|Apparent Terminal Elimination Half-life (T1/2) of MK-0941 After Multiple Doses of MK0941, Up to 72 hours after dosing (up to 24 hours for participants receiving MK0941 60 mg before 2 meals each day)|Concentration of MK-0941 at 24 Hours (C24hr) After Multiple Doses of MK-0941, Up to 72 hours after dosing (up to 24 hours for participants receiving MK0941 60 mg before 2 meals each day)
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
70
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2007-05
|
| Completion Date: |
2008-04
|
| Results First Posted: |
2012-06-26
|
| Last Update Posted: |
2016-08-24
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00511667
|
